Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.

Breast cancer research and treatment - 1 Jun 2020

Kawachi Asuka, Yamashita Satoshi, Okochi-Takada Eriko, Hirakawa Akihiro, Tsuda Hitoshi, Shimomura Akihiko, Kojima Yuki, Yonemori Kan, Fujiwara Yasuhiro, Kinoshita Takayuki, Ushijima Toshikazu, Tamura Kenji

Abstract excerpt

BACKGROUND: A PARP inhibitor is effective in breast cancer patients with BRCA1/2 germline mutations, and in cell lines with BRCA1 promoter methylation. However, its efficacy in breast cancer patients with BRCA1 promoter methylation is still unknown. METHODS: Biopsy samples were obtained from 32 triple-negative breast cancer (TNBC) patients treated with eribulin/olaparib combination therapy in a clinical trial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Furans

Share to Ketones

Share to Phthalazines

Share to Piperazines

Share to Survival Rate

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 32314111
DOI: 10.1007/s10549-020-05647-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.PMID 32314111Read ↗

Prognostic value of BRCA1 promoter methylation for patients with epithelial ovarian cancer.Semantic proximity Read ↗

BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitorsSemantic proximity Read ↗

<em>BRAC1</em> & <em>BRCA2</em> Methylation as a Prognostic and Predictive Biomarker in Cancer: Implementation in Liquid Biopsy in the Era of Precision MedicineSemantic proximity Read ↗

BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicineSemantic proximity Read ↗

BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancerSemantic proximity Read ↗

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapySemantic proximity Read ↗

BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.Semantic proximity Read ↗

Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.Semantic proximity Read ↗

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.Semantic proximity Read ↗

A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?Semantic proximity Read ↗

<i>BRCA1</i>epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancerSemantic proximity Read ↗

PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic StrategySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.